No connection

Search Results

ONMD vs RNXT

ONMD
OneMedNet Corporation
BEARISH
Price
$0.88
Market Cap
$46.0M
Sector
Healthcare
AI Confidence
95%
RNXT
RenovoRx, Inc.
BEARISH
Price
$1.00
Market Cap
$45.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ONMD
--
RNXT
--
Forward P/E
ONMD
--
RNXT
-8.33
P/B Ratio
ONMD
-15.47
RNXT
6.76
P/S Ratio
ONMD
33.88
RNXT
40.12
EV/EBITDA
ONMD
-4.83
RNXT
-3.19

Profitability

Gross Margin
ONMD
-37.01%
RNXT
70.88%
Operating Margin
ONMD
-345.9%
RNXT
-1269.75%
Profit Margin
ONMD
-206.11%
RNXT
0.0%
ROE
ONMD
--
RNXT
-225.62%
ROA
ONMD
-205.58%
RNXT
-92.59%

Growth

Revenue Growth
ONMD
3326.9%
RNXT
453.5%
Earnings Growth
ONMD
--
RNXT
--

Financial Health

Debt/Equity
ONMD
--
RNXT
0.04
Current Ratio
ONMD
0.43
RNXT
4.02
Quick Ratio
ONMD
0.22
RNXT
3.65

Dividends

Dividend Yield
ONMD
--
RNXT
--
Payout Ratio
ONMD
0.0%
RNXT
0.0%

AI Verdict

ONMD BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible financial health. With a negative Price-to-Book ratio of -15.47 and a Current Ratio of 0.43, ONMD is facing a severe liquidity crisis and possesses negative shareholder equity. While the reported revenue growth of 3326.90% is astronomical, it is offset by a negative gross margin (-37.01%) and massive operating losses, suggesting that growth is currently being achieved at an unsustainable cost. The combination of bearish insider activity and a total lack of profitability makes this a high-risk speculative asset.

Strengths
Exceptional year-over-year revenue growth (3326.90%)
Operating within the high-demand Health Information Services industry
Recent short-term price recovery (+9.7% over 1 month)
Risks
Severe liquidity risk with a Current Ratio of 0.43
Negative gross margins indicate the core product is sold at a loss
Negative equity (P/B -15.47) suggests insolvency risk
RNXT BEARISH

RNXT exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and poor operational efficiency. While the company maintains a strong liquidity position with a current ratio of 4.02 and very low debt, it is burning cash at an unsustainable rate with an operating margin of -1269.75%. The valuation is disconnected from fundamentals, trading at a Price/Sales ratio of 40.12. Despite aggressive 'strong buy' analyst targets of $6.88, the deterministic data suggests a high-risk speculative profile with a long-term bearish price trend.

Strengths
Strong short-term liquidity (Current Ratio: 4.02)
Very low leverage (Debt/Equity: 0.04)
Explosive year-over-year revenue growth (453.50%)
Risks
Extreme operational inefficiency (Operating Margin: -1269.75%)
Severe fundamental health failure (Piotroski F-Score: 1/9)
Extreme valuation premium (Price/Sales: 40.12)

Compare Another Pair

ONMD vs RNXT: Head-to-Head Comparison

This page compares OneMedNet Corporation (ONMD) and RenovoRx, Inc. (RNXT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile